$68.36
0.29% yesterday
Nasdaq, Dec 23, 10:00 pm CET
ISIN
US40637H1095
Symbol
HALO

Halozyme Therapeutics, Inc. Stock price

$68.36
-5.64 7.62% 1M
+15.56 29.47% 6M
+20.55 42.98% YTD
+21.20 44.95% 1Y
+10.87 18.91% 3Y
+25.71 60.28% 5Y
+51.37 302.35% 10Y
+66.59 3,762.15% 20Y
Nasdaq, Closing price Tue, Dec 23 2025
+0.20 0.29%

New AI Insights on Halozyme Therapeutics, Inc. Insights AI Insights on Halozyme Therapeutics, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$8.0b
Enterprise Value
$8.8b
Net debt
$808.8m
Cash
$702.0m
Shares outstanding
117.5m
Valuation (TTM | estimate)
P/E
14.1 | 10.7
P/S
6.5 | 5.9
EV/Sales
7.1 | 6.5
EV/FCF
14.7
P/B
16.0
Financial Health
Equity Ratio
17.6%
Return on Equity
122.1%
ROCE
53.3%
ROIC
-
Debt/Equity
3.0
Financials (TTM | estimate)
Revenue
$1.2b | $1.4b
EBITDA
$808.5m | $894.7m
EBIT
$737.4m | $832.3m
Net Income
$595.5m | $752.1m
Free Cash Flow
$602.4m
Growth (TTM | estimate)
Revenue
31.2% | 34.8%
EBITDA
47.5% | 43.7%
EBIT
54.6% | 50.9%
Net Income
51.7% | 69.4%
Free Cash Flow
53.4%
Margin (TTM | estimate)
Gross
84.6%
EBITDA
65.1% | 65.4%
EBIT
59.3%
Net
47.9% | 54.9%
Free Cash Flow
48.5%
More
EPS
$4.9
FCF per Share
$5.1
Short interest
14.7%
Employees
350
Rev per Employee
$2.9m
Show more

Is Halozyme Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,085 stocks worldwide.

Halozyme Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Halozyme Therapeutics, Inc. forecast:

11x Buy
73%
4x Hold
27%

Analyst Opinions

15 Analysts have issued a Halozyme Therapeutics, Inc. forecast:

Buy
73%
Hold
27%

Financial data from Halozyme Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1,243 1,243
31% 31%
100%
- Direct Costs 192 192
13% 13%
15%
1,051 1,051
35% 35%
85%
- Selling and Administrative Expenses 172 172
15% 15%
14%
- Research and Development Expense 70 70
12% 12%
6%
808 808
48% 48%
65%
- Depreciation and Amortization 71 71
0% 0%
6%
EBIT (Operating Income) EBIT 737 737
55% 55%
59%
Net Profit 595 595
52% 52%
48%

In millions USD.

Don't miss a Thing! We will send you all news about Halozyme Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Halozyme Therapeutics, Inc. Stock News

Neutral
PRNewsWire
6 days ago
RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw) SAN DIEGO , Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), which is co-formulated with ENHANZE® for pati...
Positive
Seeking Alpha
9 days ago
Halozyme is upgraded to a near-term Buy, driven by robust 2025–2028 royalty visibility and conservative valuation. HALO's acquisition of Elektrofi (Hypercon) extends IP into the 2040s, offering optionality but with uncertain long-term revenue durability. ENHANZE's U.S. patent expiry in 2027 raises post-2030 questions, but royalty streams and asset-light margins remain strong near-term.
Neutral
PRNewsWire
15 days ago
SAN DIEGO , Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:  HALO ) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 years of executive leadership experience in healthcare, life sciences, business services and data analytics.
More Halozyme Therapeutics, Inc. News

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Head office United States
CEO Helen Torley
Employees 350
Founded 1998
Website www.halozyme.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today